AROLDI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 1.242
EU - Europa 774
AS - Asia 247
SA - Sud America 3
Totale 2.266
Nazione #
US - Stati Uniti d'America 1.236
IT - Italia 302
DE - Germania 135
IE - Irlanda 131
SE - Svezia 81
CN - Cina 77
SG - Singapore 70
HK - Hong Kong 48
RU - Federazione Russa 47
GB - Regno Unito 19
IN - India 16
FI - Finlandia 15
VN - Vietnam 12
TR - Turchia 11
ID - Indonesia 9
FR - Francia 8
PT - Portogallo 7
CA - Canada 6
CZ - Repubblica Ceca 5
PL - Polonia 5
ES - Italia 4
UA - Ucraina 4
BG - Bulgaria 3
NO - Norvegia 3
IR - Iran 2
RS - Serbia 2
AR - Argentina 1
BR - Brasile 1
CH - Svizzera 1
CO - Colombia 1
DK - Danimarca 1
JP - Giappone 1
KR - Corea 1
NL - Olanda 1
Totale 2.266
Città #
Ann Arbor 545
Dublin 131
Frankfurt am Main 113
Milan 89
Chandler 86
New York 73
Fairfield 70
Wilmington 68
Woodbridge 62
Hong Kong 42
Ashburn 36
Singapore 36
Seattle 34
Houston 31
Shanghai 28
Princeton 24
Cambridge 20
Lissone 19
Monza 14
Lawrence 12
Altamura 11
Helsinki 10
Rome 9
Bologna 8
Dallas 8
Dong Ket 8
Jacksonville 8
Jakarta 8
San Diego 8
Santa Clara 8
Beijing 7
Dearborn 7
Guangzhou 7
Boardman 6
Carate Brianza 6
Fremont 6
London 6
Los Angeles 6
Turin 6
Andover 5
Munich 5
Tianjin 5
Bonndorf 4
Cinisello Balsamo 4
Como 4
Desio 4
Falls Church 4
Genoa 4
Lappeenranta 4
Lisbon 4
Lodz 4
Olomouc 4
Pune 4
Sacramento 4
Sesto San Giovanni 4
Ankara 3
Arese 3
Ceret 3
Chicago 3
Colorado Springs 3
Corbetta 3
Delhi 3
Kocaeli 3
Legnano 3
Lleida 3
Nanchang 3
Oslo 3
Sacavém 3
Seriate 3
Toronto 3
Usmate Velate 3
Agrate Brianza 2
Aurora 2
Bhopal 2
Cesano Maderno 2
Dresden 2
Haikou 2
Hounslow 2
Jiaxing 2
Jinan 2
Kragujevac 2
Latina 2
Marino 2
Marseille 2
Milton Keynes 2
Mumbai 2
Nanjing 2
Nova Milanese 2
Novara 2
Pandino 2
Pavia 2
Redmond 2
Rho 2
Rovello Porro 2
Shantou 2
Sumirago 2
Treviglio 2
Veniano 2
Vimodrone 2
Véretz 2
Totale 1.849
Nome #
Chronic myeloid leukemia: Second-line drugs of choice 263
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 182
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 176
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 173
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019 162
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 150
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea 148
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 144
Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies 128
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 105
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success 95
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 89
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 85
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 74
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 71
Idiopathic erythrocytosis: a germline disease? 52
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 51
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 51
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 44
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 39
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 38
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 27
Totale 2.347
Categoria #
all - tutte 8.695
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.695


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202097 0 1 4 10 9 12 10 17 11 13 5 5
2020/2021663 37 17 66 57 58 75 58 60 69 47 58 61
2021/2022295 52 36 48 38 14 23 4 8 7 10 17 38
2022/2023421 37 117 37 27 24 62 29 8 35 12 26 7
2023/2024650 14 20 30 27 61 175 96 25 67 42 26 67
2024/2025138 56 82 0 0 0 0 0 0 0 0 0 0
Totale 2.347